Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via...

Area of Science:

• Biochemistry
• Structural Biology
• Drug Discovery

Background:

• Human immunodeficiency virus type 1 (HIV-1) integrase (IN) is a critical target for anti-acquired immune deficiency syndrome (AIDS) therapies.
• Diketo-acid (DKA) inhibitors show promise for HIV-1 IN inhibition, but a lack of structural data hinders drug design.
• Understanding the precise inhibitory mechanisms of DKA compounds is essential for developing effective treatments.

Purpose of the Study:

• To investigate the inhibitory mechanism of raltegravir (RLV) on prototype foamy virus (PFV) IN, using it as a surrogate for HIV-1 IN.
• To explore the binding modes of DKA inhibitors with the PFV IN-DNA complex.
• To validate the PFV IN-DNA model for screening anti-AIDS drugs.

Main Methods:

• Molecular dynamics simulations of PFV IN systems with and without RLV and DNA.
• Analysis of catalytic loop flexibility and hydrogen bonding networks.
• Molecular docking of DKA inhibitors into the PFV IN-DNA complex.

Main Results:

• RLV binding reduces catalytic loop flexibility and restricts viral DNA mobility, potentially impacting IN activity.
• Docking results of DKA inhibitors with PFV IN-DNA align with known HIV-1 IN interactions.
• The PFV IN-DNA model demonstrates reliability for anti-AIDS drug screening.

Conclusions:

• The study elucidates RLV's inhibitory mechanism and validates the PFV IN-DNA system for drug discovery.
• Findings provide insights into DKA inhibitor interactions with IN.
• This research supports the rational design of novel anti-AIDS therapeutics targeting HIV-1 IN.